Protocol Ledger

NCT05418673 · Phase III · TERMINATED

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Socie

Interventional Phase III clinical trial protocol NCT05418673 sponsored by Biogen in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-26 Enrollment: 7 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05418673
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)7 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05418673
Protocol FieldVerified Registry Value
NCT IdentifierNCT05418673
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment7 participants (ACTUAL)
Registered Start Date2022-08-26
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI